Name: Allergan Inc. (NYSE:AGN.) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Allergan Inc., income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Eye Care Pharmaceuticals	3,257,900)	2,890,300)	2,692,200)	2,520,200)	2,262,000)
Botox®/Neuromodulators	2,230,600)	1,982,200)	1,766,300)	1,594,900)	1,419,400)
Skin Care and Other	523,600)	466,500)	326,100)	316,900)	292,000)
Specialty Pharmaceuticals	6,012,100)	5,339,000)	4,784,600)	4,432,000)	3,973,400)
Breast Aesthetics	406,700)	377,900)	377,100)	349,300)	319,100)
Obesity Intervention	—)	—)	159,500)	203,100)	243,300)
Facial Aesthetics	661,800)	477,500)	387,600)	362,700)	283,800)
Core Medical Devices	1,068,500)	855,400)	924,200)	915,100)	846,200)
Other	45,500)	3,100)	—)	—)	—)
Medical Devices	1,114,000)	858,500)	924,200)	915,100)	846,200)
Product net sales	7,126,100)	6,197,500)	5,708,800)	5,347,100)	4,819,600)

Download chart

Item	Description	The company
Product net sales	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Allergan Inc. product net sales increased from 2012 to 2013 and from 2013 to 2014.